CA
NZ
UK
AU
IND
US
● Iridex Corporation, the ophthalmic laser maker behind Cyclo G6 and its retina platforms, has widened a group-purchasing partnership to cover its retina products and posted its first full year of positive adjusted EBITDA in 2025, even as cash stays thin and dilution risk …
● Kairos Pharma's ENV-105 antibody, designed to reverse prostate-cancer drug resistance, has produced an 86% clinical-benefit rate in a nine-patient interim analysis. With roughly $3.7 million in cash and a going-concern warning on the books, the clinical-stage company faces a narrow runway as it …
● Peer-reviewed Phase 1 results for Kiora Pharmaceuticals' vision-restoration candidate KIO-301 appeared in Nature Medicine in April, coinciding with a Phase 2 trial that the company says is nearly half-enrolled and a $24 million financing led by Perceptive Advisors.
● Medicus Pharma's SkinJect microneedle patch cleared FDA safety review on July 27, 2026, opening the door to a registrational study in Gorlin Syndrome, days after a $22 million financing and a fresh analyst Buy initiation. The underlying Phase 2 data are real but …
Merck's Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the fourth quarter of 2026, continuing a pattern of regular capital return that has characterized the company's approach to shareholder distributions. The dividend will be …
● Acurx Pharmaceuticals says regulators have aligned on the design of pivotal phase 3 trials for its oral antibiotic ibezapolstat in C. difficile infection, while the clinical-stage company continues to raise cash through dilutive at-the-market offerings to fund the work.
● Adagio Medical has asked the FDA to approve its ultra-low-temperature ablation catheter for ventricular tachycardia after a 209-patient pivotal trial, even as cash reserves shrink and its Nasdaq-listed shares trade near record lows.
● GeoVax Labs says its cash covers operations only into September 2026, even as it prepares a pivotal Phase 3 trial for its mpox/smallpox vaccine candidate GEO-MVA following the loss of its BARDA-funded COVID-19 contract.
● GRI Bio's lead drug candidate, GRI-0621, has cleared a Phase 2a study and won FDA Orphan Drug Designation for idiopathic pulmonary fibrosis, but the microcap must still fund a costly Phase 2b trial while managing thin cash reserves and past Nasdaq compliance troubles.
● GT Biopharma dosed its second clinical-stage TriKE candidate and rolled out AI-assisted discovery tools this spring, even as cash reserves remain thin and runway guidance extends only through the fourth quarter of 2026.
Please wait processing your request...